On 8 December 2017, Knowledge Ecology International (KEI) submitted the following paper on “constraints faced by developing countries and least developed countries (LDCs) in making full use of patent flexibilities and their impacts” on access to medicines pursuant to the decision… Continue Reading
For more information, contact: (U.S.) James Love, KEI: james.love@keionline.org or +1 (202) 332-2670 (Chile) Luis Villaroel, Innovarte: info@innovarte.cl or +56 9 9827 9673 Chile FAQ What is happening in Chile with regard to HCV medicines and Xtandi, for prostate cancer?… Continue Reading
FOR IMMEDIATE RELEASE Contact: Kim Treanor kim.treanor@keionline.org; 202-332-2670 Patient groups, civil society and concerned individuals from Chile and around the world call upon President Michelle Bachelet Jeria and Dr. Carmen Castillo Taucher, Minister of Health, to issue a compulsory license… Continue Reading
In a reversal from the version that passed out of the Senate Finance Committee, the version of the tax bill that passed the Senate eliminated the requirement that the Orphan Drug tax credit be transparent as to taxpayer, drug and… Continue Reading
Attached is the Civil Society input to the 1st World Conference on Access to Medical Products and International Laws for Trade and Health in the context of the 2030 Agenda for Sustainable Development that took place in Delhi, India in… Continue Reading
In a hearing before the House Energy & Commerce Subcommittee on Health, Dr. Francis Collins, Director of the National Institutes of Health, explained the agency’s position on the Bayh-Dole rights and high drug prices. In the hearing, focused on the… Continue Reading
(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On November 30, 2017, KEI has received a response from the National Institute of Allergy and Infectious Diseases regarding our previous joint comments with MSFon the proposed exclusive… Continue Reading
The Managers Amendment for the “Tax Cuts and Jobs Act” is available on the Senate Finance web page here: https://www.finance.senate.gov/imo/media/doc/11.20.17%20Tax%20Cuts%20and%20Jobs%20Act.pdf or here: 11.20.17 Tax Cuts and Jobs Act I was looking over the Orphan Drug Tax Credit (ODTC) language. The… Continue Reading
On November 17, 2017, KEI provided comments in KEI-FDA-2017-N-3615 These were the topics discussed: Transparency Clinical trial costs Data from the Orphan Drug program Costs of trials for government funded research Asset acquisition costs. Licensing Access to Knowhow, data and materials… Continue Reading
On Monday, 27 November 2017, the WHO published the recommendations of the overall programme review of the global strategy and plan of action on public health, innovation and intellectual property (EB142/14). The full report of the overall programme review (OPR)… Continue Reading